Geron Corp (GERN) Reports In-Line Q4 EPS

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. ANET
6. DUOL
7. SWKS
8. XYZ
9. FISV
10. CVS

Go back to Geron Corp (GERN) Reports In-Line Q4 EPS

Geron Corporation Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Events

March 7, 2019 4:05 PM EST

MENLO PARK, Calif., March 07, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today reported financial results for the fourth quarter and full year ended December 31, 2018 and recent events. As of year-end 2018, the Company had approximately $182 million in cash and marketable securities, which is sufficient to commence the planned Phase 3 clinical trial of imetelstat in lower risk myelodysplastic syndromes (MDS) by mid-year 2019.

We expect 2019 to be a pivotal year, said John A. Scarlett, M.D., Chairman and Chief Executive Officer. We are making good progress in the transition of the imetelstat program and expect to... More